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Background: Plasmodium vivax continues to be the most widely distributed malarial parasite species in tropical
and sub-tropical areas, causing high morbidity indices around the world. Better understanding of the proteins used
by the parasite during the invasion of red blood cells is required to obtain an effective vaccine against this disease.
This study describes characterizing the P. vivax asparagine-rich protein (PvARP) and examines its antigenicity in
natural infection.
Methods: The target gene in the study was selected according to a previous in silico analysis using profile hidden
Markov models which identified P. vivax proteins that play a possible role in invasion. Transcription of the arp gene
in the P. vivax VCG-1 strain was here evaluated by RT-PCR. Specific human antibodies against PvARP were used to
confirm protein expression by Western blot as well as its subcellular localization by immunofluorescence.
Recognition of recombinant PvARP by sera from P. vivax-infected individuals was evaluated by ELISA.
Results: VCG-1 strain PvARP is a 281-residue-long molecule, which is encoded by a single exon and has an
N-terminal secretion signal, as well as a tandem repeat region. This protein is expressed in mature schizonts and is
located on the surface of merozoites, having an apparent accumulation towards their apical pole. Sera from
P. vivax-infected patients recognized the recombinant, thereby suggesting that this protein is targeted by the
immune response during infection.
Conclusions: This study showed the characterization of PvARP and its antigenicity. Further assays orientated
towards evaluating this antigen’s functional importance during parasite invasion are being carried out.
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Malaria is a tropical disease that causes millions of deaths
per year around the world. The World Health Organiza-
tion’s (WHO) Malaria Report 2011 indicated that there
were 216 million cases and 655,000 deaths, mainly in chil-
dren aged less than five years [1]. In spite of the incidence
of cases worldwide and mortality index having become
substantially reduced by 17% and 25% between 2000 and
2010, respectively, the figures regarding cases of malaria
continue to be alarming. This is due to two main aspects
impeding the total eradication of the disease: a gradual in-
crease of parasite strains which are resistant to anti-
malarial drugs [2] and populations of the mosquito vector
which are insecticide-resistant [3].* Correspondence: mapatarr.fidic@gmail.com
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distribution, and reproduction in any mediumPlasmodium vivax stands out as the most widespread
parasite species causing malaria in humans; it is found
throughout tropical and subtropical areas of the world
and causes the disease’s highest morbidity indices on the
Asian and American continents [4]. Even though it has
been thought that P. vivax was a benign species, recent
studies have shown that infection caused by this parasite
could cause severe clinical symptoms [5,6], similar to
those found in Plasmodium falciparum infection, thereby
making it a potential menace.
Synthetic vaccines have been considered a good choice
among control strategies when combating infectious dis-
eases. Regarding malarial blood stages, vaccine develop-
ment has been focused on the recombinant expression of
parasite antigens (MSP-1 [7-9] and AMA-1 [10,11] having
been the most studied) or on using synthetic peptidesentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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cies has been reported to date.
Recent work has established that the key to achieving an
effective vaccine lies in blocking the interaction of parasite
ligands which facilitate adhesion to target cell receptors
[14]; this means that molecules localized on parasite surface
and apical organelles (rhoptries and micronemes) must be
identified. Unfortunately, data regarding the P. vivax pro-
teins involved in invasion of reticulocytes that have been
functionally characterized to date lag behind that available
for their P. falciparum counterparts [15]. The foregoing has
been due to the difficulty of standardizing an in vitro cul-
ture given poor reticulocyte recovery from adult human
total blood [16]. Such experimental limitation has led to
several study alternatives having been suggested; probabilis-
tic techniques have been most useful when predicting pos-
sible vaccine candidates. A recent study involving hidden
Markov models for analyzing the transcriptome of the
P. vivax Sal-1 strain’s intra-erythrocyte life-cycle has led to
the identification of 45 proteins that play a potential role in
invasion; the role in cell adhesion for 13 of them (localized
in merozoite rhoptries or on their surface) had previously
been determined [17]. It was particularly interesting that an
asparagine-rich protein (ARP) was found, this being con-
served throughout the Plasmodium genus [17]. Only its
P. falciparum orthologue has been described to date, called
the apical asparagine-rich protein (PfAARP) [18]. The
PfAARP-encoding gene has a prominent expression pattern
towards the last intra-erythrocyte parasite development
stage (48 hours post-invasion), which has been shown by
real-time PCR and Northern blot. Antigenicity assays have
shown that the N-terminal protein’s region (PfAARP-N)
obtained as a recombinant is recognized by antibodies from
patients who have been naturally infected by P. falciparum.
Rabbit antibodies directed against PfAARP-N have been
able to significantly inhibit parasite invasion of RBC
in vitro. The foregoing, together with an RBC binding assay
involving the expression of the complete protein on COS
cell surface, has highlighted this antigen’s functional role in
parasite binding to and invasion of target cells [18].
The present study was thus aimed at characterizing the
asparagine-rich protein orthologue for PfAARP in P. vivax.
Molecular biology assays and immunochemistry techniques
were used to demonstrate Pvarp gene transcription, protein
expression and localization, as well as the ability to induce
an antigenic response in patients who had suffered episodes
of P. vivax malaria.
Methods
Selecting the gene and designing the primers and
synthetic peptides
PvARP was selected, bearing in mind the in silico study
by Restrepo-Montoya et al. [17] of P. vivax proteins
playing a potential role in invasion. The PlasmoDB [19]database was then scanned to obtain the Pvarp gene se-
quence from the Salvador 1 (Sal-1) reference strain and to
analyze adjacent genes’ synteny in different Plasmodium
species. Specific primers were designed manually using
Gene Runner software (version 3.05). B-cell lineal epitopes
were predicted with AntheProt software [20] using the de-
duced amino-acid (aa) sequence. A tBlastn analysis of the
predicted B-cell epitopes was then carried out to select
peptide sequences exclusive for the P. vivax ARP.
Animal handling
The experimental animals used were handled in accord-
ance with Colombian Law 84/1989 and resolution 504/
1996. Aotus monkeys kept at FIDIC’s primate station
(Leticia, Amazon) were handled following established
guidelines for the care and use of laboratory animals
(National Institute of Health, USA) under the constant
supervision of a primatologist. All experimental proce-
dures involving Aotus monkeys had been previously ap-
proved by the Fundación Instituto de Inmunología's
ethics committee and were carried out in agreement
with the conditions stipulated by CorpoAmazonia (reso-
lution 00066, 13 September, 2006). An Aotus monkey
was experimentally infected with the Vivax Colombia
Guaviare 1 (VCG-1) strain and monitored daily to assess
infection progress throughout the entire study (up to
day 18) using Acridine Orange staining. The monkey was
treated with paediatric doses of chloroquine (10 mg/kg on
the first day and 7.5 mg/kg/day until the fifth day) and
primaquine (0.25 mg/kg/day from the third to the fifth
day) at the end of the study to guarantee parasite clear-
ance from total blood. Once experiments were over,
CorpoAmazonia officers supervised the primate’s return
to its natural habitat in excellent health.
Isolating the Plasmodium vivax parasite
VCG-1 strain parasites were maintained in vivo according
to previously described methodology [21]. A P. vivax-
infected blood sample (3 mL) was passed through a dis-
continuous Percoll gradient (GE Healthcare, Uppsala,
Sweden) according to an already established protocol [22]
for obtaining schizont-stage enriched parasite. The sample
was then used as RNA, genomic DNA (gDNA) and total
protein source.
Extracting RNA and cDNA synthesis
Total RNA was extracted from the schizont-enriched
sample using the Trizol method and treated with RQ1
(RNA-qualified) RNase-free DNase (Promega, Wisconsin,
USA) according to the manufacturer’s recommendations.
Complementary DNA (cDNA) was synthesized using a
SuperScript III enzyme (RT+) (Invitrogen, California,
USA) in the following conditions: 65°C for 5 min, 50°C for
1 hour and 70°C for 15 min. An additional reaction
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use as control. Following 15 min’ incubation at 37°C with
RNase (Promega, USA) the product was stored at −70°C
until its later use.
Cloning, sequencing and bioinformatics analysis
The cDNA RT + and RT- samples, as well as the gDNA
obtained using a DNA Wizard Genomic purification kit
(Promega), were used as template in 10 μL PCR reactions
containing 0.5 U/μL Accuzyme DNA polymerase (Bioline),
1x AccuBuffer, 2 mM MgCl2, 0.5 mM dNTP, 0.5 μM
primers and DNAse-free water for completing the reaction
volume. Specific primers were designed for amplifying a re-
gion containing the entire Pvarp gene (direct 5′- CATTT
GATCAGAGACGAC -3′ and reverse 5′- TTGGCACTTT
TGTCACGA -3′), or the encoding sequence without the
signal peptide (direct 5′- atgTGCAACACAAATGGGA
AAA -3′ and reverse 5′- CACGCCAAACAGCTTCA -3′);
the protein expression start codon was included in the dir-
ect primer’s 5′ end. A set of primers which had been previ-
ously designed for amplifying the Pvron1-a region (direct
5′- atgGCGAAGGAGCCCAAGTG-3′ and reverse 5′- AT
CCCTAGCAATGCTTCG -3′) [23] was used as control for
cDNA contamination with gDNA. The PCR for the Pvarp
gene began with a denaturing step at 95°C for 5 min,
followed by 35 cycles at 95°C for 30 sec, 52°C for 10 sec
and 72°C for 1 min. Pvron1-a PCR began with a denaturing
step at 95°C for 5 min, followed by 35 cycles at 95°C for
30 sec, 56°C for 10 sec and 72°C for 1.5 min. A Wizard
PCR preps kit (Promega) was used for purifying Pvarp gene
amplicons obtained from independent PCRs done with the
RT + sample, once quality had been evaluated by 1% agar-
ose gel. Pure products were then ligated to the pEXP5 CT/
TOPO expression vector and transformed in TOP10
Escherichia coli cells (Invitrogen). Various clones were
grown to purify the plasmid, using an UltraClean mini plas-
mid prep purification kit (MO BIO laboratories, California,
USA); insert integrity and its correct orientation were con-
firmed by sequencing using an ABI PRISM 310 genetic
analyzer (PE Applied Biosystems, California, USA). VCG-1
strain PvARP was characterized in silico using SignalP 3.0
[24], FragAnchor [25], XSTREAM [26], tools and the
Interpro database [27] to search for secretion signal or
GPI-anchor sequences, tandem repeats and putative do-
mains, respectively. Clustal W software was used for
aligning genes and pertinent encoding sequences [28].
Recombinant protein expression and purification
The pEXP5-PvARP recombinant plasmid which encodes
the entire PvARP sequence without the signal peptide (con-
firmed by sequencing) was transformed in E. coli BL21-AI
(Invitrogen), according to the manufacturer’s recommenda-
tions. A protocol described by Sivashanmugam and his
group [29] with some modifications, was used forimproving expression yield. Briefly, the cells were grown
overnight at 37°C in 10 mL Luria Bertani (LB) medium
containing 100 μg/mL ampicillin and 0.1% (w/v) D-
glucose. The initial inoculum was then seeded in 100 mL
LB volume with the same amount of the aforementioned
ampicillin and D-glucose and left to grow at 37°C
using ~300 rpm until reaching 0.5 OD600; 0.2% L-arabin-
ose (w/v) was used for five hours to induce expression.
The culture was spun at 13,000 rpm for 30 min and lysed
in extraction buffer (EB) (6 M urea, 12 mM imidazole,
10 mM Tris-Cl, 100 mM NaH2PO4 and 10 mg/mL lyso-
zyme) supplemented with protease inhibitors (1 mM
PMSF, 1 mM iodoacetamide, 1 mM EDTA and 1 mg/mL
leupeptin). PvARP recombinant expression (rPvARP) was
verified by Western blot and the protein was then purified
by solid-phase affinity chromatography using Ni+2-NTA
resin (Qiagen, California, USA) following the manufac-
turer’s recommendations. Briefly, total lysate was incu-
bated with the resin pre-equilibrated with EB overnight at
4°C. The rPvARP mixture coupled to the resin was placed
on a column and then washed several times with EB to
eliminate weakly bound proteins. The recombinant pro-
tein was eluted with EB containing imidazole at differing
concentrations (20, 100, 250 and 500 mM) in 3 mL frac-
tions, which were analyzed by Coomassie blue staining to
verify the presence of a single band and then dialyzed
in PBS, pH 7.0. A micro BCA protein assay kit (Thermo
Scientific) was used for quantifying every fraction so
obtained; a bovine serum albumin (BSA) curve was used
as reference.
Peptide synthesis and obtaining polyclonal antibodies
A 20 aa-long peptide (predicted to be a good B-cell
epitope), located at the N-terminus of PvARP (CG-
LDNLKAKESPSSNDDGVYAKG-GC), was synthesized
according to a previously-established methodology [30], po-
lymerized, lyophilized and characterized by RP-HPLC and
MALDI-TOF MS. Five mg of peptide (called 38582 herein)
were immobilized on a CNBr-activated Sepharose 4B col-
umn, according to the manufacturer’s recommendations. A
pool of fifteen sera taken from patients who had suffered
previous P. vivax malarial episodes (stored in FIDIC’s
serum-bank, see the ‘Sample source’ section) was incubated
with the peptide coupled to a Sepharose 4B column over-
night at 4°C with constant shaking to purify specific anti-
bodies against peptide 38582 (anti-PvARP38582). The
retained antibodies were eluted with gradients of increasing
salt concentration (50 mM-0.3 M NaCl); they were then di-
alyzed in PBS, pH 7.8, and stored at −20°C until use.
SDS-PAGE and Western blot
Five μg rPvARP and 50 μg total parasite proteins were
separated on 12% SDS-PAGE and then transferred to
nitrocellulose membranes. After having been blocked with
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membrane was cut into strips and individually analyzed as
follows: strips with the recombinant protein were incu-
bated for two hours at room temperature (RT) with anti-
PvARP38582 serum fractions (1:100 dilution) in a solution
of 5% skimmed milk in PBS-0.05% Tween to assess which
of them contained anti-PvARP specific antibodies; one
strip was incubated with an anti-histidine monoclonal
antibody coupled to peroxidase (1:4,500) as positive con-
trol for Western blot. Serum fractions recognizing the re-
combinant protein were then used to detect PvARP in
total parasite lysate in the aforementioned conditions.
Once antibody reactivity had been eliminated by incubat-
ing anti-PvARP38582 serum with peptide 38582 for one
hour at 37°C, then this solution was used as control. Fol-
lowing three washes with PBS-0.05% Tween (5 min per
wash), the strips were incubated for one hour with
phosphatase-conjugated goat anti-human IgG as second-
ary antibody (1:5,000) at RT. The blots were revealed with
a VIP peroxidase (Vector Laboratories, Burlingame,
Canada) or BCIP/NBT colour development substrate kits
(Promega), according to the manufacturers’ indications.
Indirect immunofluorescence assay (IFA)
Plasmodium vivax-parasitized reticulocytes were washed
thrice with PBS and then diluted in this solution until
obtaining five to seven schizonts per field evaluated by
staining with Acridine orange. Twenty μL of the sample
were fed per well on eight-well multitest glass slides
(Biomedicals, Inc) and the supernatant was removed
10 min later. Once the samples were dry, they were fixed
with 4% formaldehyde for 5 min at RT. Following five
washes with PBS, the sample was incubated with 1% Tri-
ton X-100 for 5 min in the previously described condi-
tions. After 10-min blocking at RT with 1% (v/v) skimmed
milk in PBS, each sample was incubated for one hour at
RT with anti-PvARP38582 antibodies (20 μL). The samples
were then incubated with FITC-conjugated anti-human
IgG antibody (Sigma) at 1:30 dilution for 45 min in the
dark. The DNA was stained with DAPI (0.5 μg/mL) for
10 min at RT and the excess was removed by washing sev-
eral times with PBS-0.05% Tween. Once the slides had
been examined under an Olympus BX51 florescence
microscope (using 100× oil immersion objective), Volocity
software (version 5.3.2) was used for superimposing
the images.
Enzyme-linked immunosorbent assay (ELISA)
PvARP antigenicity was evaluated in triplicate using
serum from patients who had been living in malaria-
endemic areas in Colombia and had presented episodes
of such infection. Sera taken from healthy individuals who
had never suffered the disease were used as negative con-
trols. Briefly, 96-well polysorb plates were covered with1 μg/mL rPvARP overnight at 4°C and then incubated
at 37°C for one hour. The dishes were blocked with 200 μL
5% skimmed milk - PBS-0.05% Tween for one hour at
37°C. Antibody reactivity against the recombinant protein
was evaluated by incubating the plates with a 1:100 dilution
of each human serum in 5% skimmed milk -PBS-0.05%
Tween for one hour at 37°C. Following incubation of the
dishes with peroxidase-coupled anti-human IgG secondary
antibody (1:10,000) diluted in 5% skimmed milk - PBS-
0.05% Tween for one hour at 37°C, a peroxidase substrate
solution (KPL Laboratories, WA, USA) was added to re-
veal the reaction, according to the manufacturer’s recom-
mendations. Optical density (OD) was detected at 620 nm
with an MJ ELISA multiskan reader and then calculated by
subtracting the OD value obtained from the control well
(no antigen). A 0.11 cut-off value for evaluating the positiv-
ity threshold was determined by taking the average of the
OD plus twice the standard deviation (2 ± SD) of healthy
individuals’ sera reactivity.
Statistical analysis
Differences in average OD for rPvARP recognition by
P. vivax-infected patients’ sera and in the control group
were evaluated using the Kruskal-Wallis rank-sum test. A
0.05 significance level was used for testing a stated
hypothesis.
Sample source
Sera were obtained from 38 patients who were living in
malaria-endemic areas of Colombia and who had suffered
previous episodes of P. vivax malaria (but not P. falcip-
arum), as well as from 15 healthy individuals who had
never been affected by the disease. All individuals signed
an informed consent form after receiving detailed infor-
mation regarding the study’s goals.
Accession number
The nucleotide and aa sequences used here have been
reported in the GenBank database, under accession
number KC514070.
Results and discussion
Analyzing the arp gene in Plasmodium species
The P. vivax proteins identified as playing a potential role
in invasion by profile hidden Markov models [17] led to
PvARP being selected. According to the information pro-
vided by the PlasmoDB database, the Pvarp gene (access
number: PVX_090210) was found to be located between
base pairs 1,230,371 and 1,231,228 in chromosome 5 of
the Sal-1 strain. Similar genes were also found in the gen-
ome of other Plasmodium species known to be causing
malaria in humans (P. falciparum and Plasmodium
knowlesi), apes (Plasmodium cynomolgi) and rodents
(Plasmodium berghei, Plasmodium yoelii and Plasmodium
Figure 1 Pvarp gene transcription during blood stage. Lane 1
indicates the molecular weight marker. Lanes 2–4 show Pvarp gene
amplification using cDNA RT+, RT- and gDNA, respectively. Lanes
6–8 show the amplification of the Pvron1-a region using cDNA RT+,
RT- and gDNA as template, respectively. Lane 5 shows the negative
control for amplifying the Pvarp gene.
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dified product was 61.19%, identical to its orthologue in
P. knowlesi (PKH_052690), 53.15% to its orthologue
in P. cynomolgi (PCYB_053680) and 33.68% to its
orthologue in P. falciparum (PF3D7_0423400), while iden-
tity ranged from 23.61% to 22.22% regarding orthologues
in P. chabaudi (PCHAS_052400), P. yoelii (PY06454) and
P. berghei (PBANKA_052380). Such genes were located in
a syntenic region, as corroborated by their open reading
frame orientation and exon-intron structure. The forego-
ing supported the idea that the Pvarp gene has been de-
rived from a common ancestor; however, experimental
evidence concerning the functional role that the encoded
protein might have in different parasite species remains to
be determined.The Pvarp gene is transcribed in schizonts
The presence of Pvarp gene transcripts in the P. vivax
VCG-1 strain was confirmed by PCR using the cDNA from
a parasite sample as template. Figure 1 shows the Pvarp
gene amplification products (excluding the signal peptide-
encoding region) (lanes 2–4) and the Pvron1 gene’s aTable 1 Mutations found in VCG-1 strain PvARP nucleotide an
(Sal-1)
Base pairs* Amino acids* Mutations/
Deletions
Changes in Pvarp nu
in P. viva
Sal-I
456 152 Synonymous CAT
600-611 200-204 Deletion CATGAACGGAAA
650 216 Synonymous TAT
651 217 Non-synonymous GAA
655-656 218 Synonymous CGG
657 219 Non-synonymous AAA
663 221 Synonymous AAC
*Nucleotide and amino acid positions are numbered according to PvARP in the Sal-region (lanes 5–8) from cDNA and gDNA. A ~810 bp band
(Figure 1; lane 2) obtained from cDNA amplification (RT+)
showed that the Pvarp gene was transcribed in the
schizont-enriched sample, similar to that reported in the
transcriptional profile for the Sal-1 strain showing a max-
imum transcription level after 35 hours of intra-erythrocyte
life cycle [31]. It was also confirmed that the Pvarp gene
was encoded by a single exon once the sequences obtained
from cDNA and gDNA products (Figure 1; lanes 2 and 4)
had been aligned. The presence of a single ~1,053 bp band
in Pvron1-a PCR (Figure 1; lane 6) indicated that the cDNA
had not been contaminated by gDNA given that the
expected product for the latter would have been ~1,559 bp
(Figure 1; lane 8). No amplification was observed in the
negative controls for each PCR (Figure 1; lanes 3 and 7
(RT-), and 5 (DNA-free water)).
Comparing Aotus monkey-adapted VCG-1 strain Pvarp
gene sequences to those from the Sal-1 reference strain led
to identifying four synonymous mutations, two non-
synonymous ones producing aa changes (i e, methionine
(M) for asparagine (N) and glycine (G) for N in aa position
217 and 219, respectively) and a 12-base pair deletion
related to an asparagine-methionine-asparagine-glycine
(NMNG) repeat block (Table 1). It has been found that
parasite proteins have both highly polymorphic and con-
served regions; the former are the target for an immune re-
sponse while conserved sequences implicated in interaction
with cell receptors are usually not antigenic [32]. Consider-
ing that the latter regions might be suitable targets for
blocking parasite entry to host cells, further studies aimed
at evaluating Pvarp gene polymorphism in different isolates
are required to determine which sequences could be used
as components of a vaccine against malaria caused by
P. vivax.Characterizing PvARP in silico
The VCG-1 strain Pvarp gene encoded a 281 aa long pro-
tein having ~30 kDa molecular mass, this being 64 residuesd amino acid sequences regarding the reference strain
cleotide sequences
x strains
Changes in the PvARP amino acid sequences










Figure 2 In silico characterization of PvARP, showing signal peptide localization, tandem repeats (TR), asparagine (ARR) and proline
(PRR) amino acid repeat regions and the peptide selected for the antibody purification assay (shown in the box).
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[18]. PvARP consists of 20% asparagine residues and has a
signal peptide with a cleavage site between aa TNG-KS
(Figure 2). A post-translational modification false positive
consisting of a C-terminal glycosylphosphatidylinositol
(GPI) anchor sequence has been predicted [17], differing to
its P. falciparum homologue which has a true positive one.
Asparagine- and proline-rich regions were found towards
the C-terminal extreme of the protein sequence; the first of
these covered residues 212 to 235, while the another one
was found downstream between aa 242 and 259 (Figure 2).
Additionally, a tandem repeat region (TR), a feature shared
with other vaccine candidates described to date, was also
found using XSTREAM software [26] (Figure 2); this region
consisted of 11 repeat blocks from the (D/N/S)(V/M)NG
consensus sequence found in aa 168 to 211. The sequence
was seen to be exclusive for P. vivax and had mutations
(two substitutions and four deletions), thereby suggesting
that it was under pressure from the immune system. TR
have been common in several P. vivax antigens described
to date, which are mainly located on the surface or in apical
organelles; these would include the circumsporozoite pro-
tein (CSP) [33], merozoite surface protein 9 (MSP-9) [34],
Pv34 [35] and rhoptry neck proteins 1 and 2 [23,36]. EvenFigure 3 Detecting recombinant and parasite protein by human antib
show non-induced and induced cell lysate, respectively (Coomassie stainin
analyzed by Western blot using anti-polyhistidine antibodies, respectively. (
PvARP by Western blot, respectively. Lane 2 shows the absence of human
indicates PvARP recognition. Lane 4 shows detection of recombinant prote
in kDa.though several studies have shown that the tandem repeats
of PvCSP trigger an immune response when inoculated in
primates and humans [33,37,38], the response so produced
did not completely inhibit infection caused by the parasite.
It has been shown in other Plasmodium species that TR
could act as a smokescreen against the immune system,
thereby diverting strong reactions towards functionally-
relevant regions [39]; however, their exact role in P. vivax
antigens remains unknown.
PvARP expression in schizonts and subcellular localization
Specific human antibodies against an N-terminal PvARP
synthetic peptide (Figure 2) were used for checking pro-
tein expression and localization in the schizont-enriched
sample. PvARP was recombinantly expressed excluding
the signal peptide and then purified (Figure 3A). Once hu-
man anti-PvARP38582 antibody ability to detect the recom-
binant protein in Western blot assays had been checked
(Figure 3B), they were then used for detecting the protein
on a blot containing parasite total lysate (Figure 3C). Both
the parasite and recombinant PvARP proteins were
detected above the expected weight (~40 and ~49 kDa, re-
spectively), probably due to the presence of acidic aa
(aspartic acid and glutamic acid) thereby causingodies. (A) Recombinant protein expression and purification. Lanes 2–3
g). Lanes 4–5 show purified rPvARP stained with Coomassie or
B and C) Antibody ability to recognize recombinant and parasite
serum reactivity after being pre-incubated with peptide 38582. Lane 3
in (positive control). MW kDa indicates molecular weight marker
Figure 4 PvARP sub-cellular localization in mature schizonts. (A) Shows the detection of the protein on free merozoite surface. (B) PvARP
labelling on mature schizonts. The nuclei are labelled with DAPI (blue). An amplified image of a merozoite (indicated by an arrow) is shown in
small boxes.
Figure 5 rPvARP antigenicity. The box diagram shows OD
distribution (Y axis) for detecting rPvARP by sera from non-infected and
infected individuals (X axis). *: Infected individuals (n = 38; X̄±S = 0.5 ±
0.2; 95%CI = 0.16-1.1) and control (n = 15; X̄±S = 0.1 ± 0.07; 95%IC =
0.03-0.24). p value = 0.000.
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had specific reactivity to a ~40 kDa band; such reactivity
was eliminated by using serum which had been pre-
incubated with peptide 38582 (Figure 3C; lane 2).
A strong fluorescence signal, having an apparent con-
centration towards the apical pole, was found on free mer-
ozoites’ surface and in mature schizonts when using the
serum as primary antibody in the parasitized reticulocyte
sample (Figure 4). The results led to the suggestion that
PvARP could be expressed in apical organelles and then
become relocated to the surface. However, other confocal
or electron microscope assays are needed to determine
the protein’s exact localization pattern.
Antigenicity in humans
PvARP antigenic ability was evaluated by ELISA, using the
sera from 38 patients who had suffered P. vivax malaria
and 15 serum samples from people who had never suffered
from the disease. The statistical test revealed a statistically
significant difference between the medians (m) of the
groups (Wilcoxon rank-sum test. Z = 5.1, p = 0.000); it gave
m = 0.5 for the group of infected patients and m = 0.1 for
the control group (Figure 5), thereby corroborating the fact
that the protein was able to trigger an antibody response in
the host during natural P. vivax malaria infection, most sera
being able to recognize native and recombinant protein, as
demonstrated by IFA and Western blot, respectively. The
results supported the idea of analyzing this protein’s poten-
tial as a candidate for an anti-P. vivax vaccine.
Conclusions
This study has described how the P. vivax asparagine-
rich protein was characterized. As demonstrated, PvARPwas conserved among different species belonging to the
Plasmodium genus and shared some features of well-
characterized surface and/or apical proteins being studied
as candidates for a vaccine, such as prominent transcrip-
tion and expression towards the end of the intra-
erythrocyte life cycle and broad recognition by sera from
patients infected with P. vivax malaria. The results sup-
ported the notion that this antigen could be a promising
candidate for inclusion when developing an anti-malarial
vaccine. Further immunogenicity assays and studies of the
ability to induce protection in the experimental Aotus
model are required.
Moreno-Pérez et al. Malaria Journal 2013, 12:165 Page 8 of 9
http://www.malariajournal.com/content/12/1/165Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
DAMP designed experiments, analyzed data and wrote the initial manuscript.
AS carried out molecular biology and immunochemical assays. MAP
designed, evaluated and coordinated the assays and corrected the final
manuscript. All authors read and approved the final manuscript.
Acknowledgements
We would like to thank Daniela Prieto Borja for her technical support, Jason
Garry for translating and reviewing this manuscript and especially Prof
Manuel Elkin Patarroyo for his invaluable comments and suggestions. This
research was supported by the “Instituto Colombiano para el Desarrollo de la
Ciencia ‘Francisco José de Caldas” (COLCIENCIAS) contract RC#309-2013.
Received: 28 January 2013 Accepted: 12 May 2013
Published: 20 May 2013
References
1. WHO: World malaria report. Geneva: World Health Organization; 2011.
2. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F,
Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K,
Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N,
Socheat D, White NJ: Artemisinin resistance in Plasmodium falciparum
malaria. N Engl J Med 2009, 361:455–467.
3. Hunt RH, Fuseini G, Knowles S, Stiles-Ocran J, Verster R, Kaiser ML, Choi KS,
Koekemoer LL, Coetzee M: Insecticide resistance in malaria vector
mosquitoes at four localities in Ghana, West Africa. Parasit Vectors 2011, 4:107.
4. Guerra CA, Howes RE, Patil AP, Gething PW, Van Boeckel TP, Temperley WH,
Kabaria CW, Tatem AJ, Manh BH, Elyazar IR, Baird JK, Snow RW, Hay SI: The
international limits and population at risk of Plasmodium vivax
transmission in 2009. PLoS Negl Trop Dis 2010, 4:e774.
5. Genton B, D’Acremont V, Rare L, Baea K, Reeder JC, Alpers MP, Muller I:
Plasmodium vivax and mixed infections are associated with severe
malaria in children: a prospective cohort study from Papua New Guinea.
PLoS Med 2008, 5:e127.
6. Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M,
Lampah DA, Price RN: Multidrug-resistant Plasmodium vivax associated
with severe and fatal malaria: a prospective study in Papua, Indonesia.
PLoS Med 2008, 5:e128.
7. Barrero CA, Delgado G, Sierra AY, Silva Y, Parra-Lopez C, Patarroyo MA:
Gamma interferon levels and antibody production induced by two
PvMSP-1 recombinant polypeptides are associated with protective
immunity against P. vivax in Aotus monkeys. Vaccine 2005, 23:4048–4053.
8. Sierra AY, Barrero CA, Rodriguez R, Silva Y, Moncada C, Vanegas M,
Patarroyo MA: Splenectomised and spleen intact Aotus monkeys’
immune response to Plasmodium vivax MSP-1 protein fragments and
their high activity binding peptides. Vaccine 2003, 21:4133–4144.
9. Xue X, Ding F, Zhang Q, Pan X, Qu L, Pan W: Stability and potency of the
Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate
with Montanide ISA720 adjuvant. Vaccine 2010, 28:3152–3158.
10. Gentil F, Bargieri DY, Leite JA, Francoso KS, Patricio MB, Espindola NM, Vaz
AJ, Palatnik-de-Sousa CB, Rodrigues MM, Costa FT, Soares IS: A recombinant
vaccine based on domain II of Plasmodium vivax Apical Membrane
Antigen 1 induces high antibody titres in mice. Vaccine 2010,
28:6183–6190.
11. Dicko A, Diemert DJ, Sagara I, Sogoba M, Niambele MB, Assadou MH,
Guindo O, Kamate B, Baby M, Sissoko M, Malkin EM, Fay MP, Thera MA,
Miura K, Dolo A, Diallo DA, Mullen GE, Long CA, Saul A, Doumbo O, Miller
LH: Impact of a Plasmodium falciparum AMA1 vaccine on antibody
responses in adult Malians. PLoS One 2007, 2:e1045.
12. Herrera S, Bonelo A, Perlaza BL, Valencia AZ, Cifuentes C, Hurtado S,
Quintero G, Lopez JA, Corradin G, Arevalo-Herrera M: Use of long synthetic
peptides to study the antigenicity and immunogenicity of the Plasmodium
vivax circumsporozoite protein. Int J Parasitol 2004, 34:1535–1546.
13. Patarroyo ME, Patarroyo MA: Emerging rules for subunit-based,
multiantigenic, multistage chemically synthesized vaccines. Acc Chem Res
2008, 41:377–386.
14. Patarroyo ME, Bermudez A, Patarroyo MA: Structural and immunological
principles leading to chemically synthesized, multiantigenic, multistage,minimal subunit-based vaccine development. Chem Rev 2011,
111:3459–3507.
15. Patarroyo MA, Calderon D, Moreno-Perez DA: Vaccines against Plasmodium
vivax: a research challenge. Expert Rev Vaccines 2012, 11:1249–1260.
16. Udomsangpetch R, Kaneko O, Chotivanich K, Sattabongkot J: Cultivation of
Plasmodium vivax. Trends Parasitol 2008, 24:85–88.
17. Restrepo-Montoya D, Becerra D, Carvajal-Patino JG, Mongui A, Nino LF,
Patarroyo ME, Patarroyo MA: Identification of Plasmodium vivax proteins
with potential role in invasion using sequence redundancy reduction
and profile hidden Markov models. PLoS One 2011, 6:e25189.
18. Wickramarachchi T, Devi YS, Mohmmed A, Chauhan VS: Identification and
characterization of a novel Plasmodium falciparum merozoite apical protein
involved in erythrocyte binding and invasion. PLoS One 2008, 3:e1732.
19. PlasmoDB: plasmodium genomics resource. http://www.plasmodb.org.
20. Deleage G, Combet C, Blanchet C, Geourjon C: ANTHEPROT: an integrated
protein sequence analysis software with client/server capabilities.
Comput Biol Med 2001, 31:259–267.
21. Pico de Coana Y, Rodriguez J, Guerrero E, Barrero C, Rodriguez R, Mendoza
M, Patarroyo MA: A highly infective Plasmodium vivax strain adapted to
Aotus monkeys: quantitative haematological and molecular
determinations useful for P. vivax malaria vaccine development.
Vaccine 2003, 21:3930–3937.
22. Andrysiak PM, Collins WE, Campbell GH: Concentration of Plasmodium
ovale- and Plasmodium vivax-infected erythrocytes from nonhuman
primate blood using Percoll gradients. Am J Trop Med Hyg 1986,
35:251–254.
23. Moreno-Perez DA, Montenegro M, Patarroyo ME, Patarroyo MA:
Identification, characterization and antigenicity of the Plasmodium vivax
rhoptry neck protein 1 (PvRON1). Malar J 2011, 10:314.
24. Bendtsen JD, Nielsen H, von Heijne G, Brunak S: Improved prediction of
signal peptides: SignalP 3.0. J Mol Biol 2004, 340:783–795.
25. Poisson G, Chauve C, Chen X, Bergeron A: FragAnchor: a large-scale
predictor of glycosylphosphatidylinositol anchors in eukaryote protein
sequences by qualitative scoring. Genomics Proteomics Bioinformatics 2007,
5:121–130.
26. Newman AM, Cooper JB: XSTREAM: a practical algorithm for identification
and architecture modeling of tandem repeats in protein sequences.
BMC Bioinformatics 2007, 8:382.
27. Hunter S, Apweiler R, Attwood TK, Bairoch A, Bateman A, Binns D, Bork P,
Das U, Daugherty L, Duquenne L, Finn RD, Gough J, Haft D, Hulo N, Kahn D,
Kelly E, Laugraud A, Letunic I, Lonsdale D, Lopez R, Madera M, Maslen J,
McAnulla C, McDowall J, Mistry J, Mitchell A, Mulder N, Natale D, Orengo C,
Quinn AF, Selengut JD, Sigrist CJ, Thimma M, Thomas PD, Valentin F, Wilson
D, Wu CH, Yeats C: InterPro: the integrative protein signature database.
Nucleic Acids Res 2009, 37:D211–D215.
28. Thompson JD, Higgins DG, Gibson TJ: CLUSTAL W: improving the
sensitivity of progressive multiple sequence alignment through
sequence weighting, position-specific gap penalties and weight matrix
choice. Nucleic Acids Res 1994, 22:4673–4680.
29. Sivashanmugam A, Murray V, Cui C, Zhang Y, Wang J, Li Q: Practical
protocols for production of very high yields of recombinant proteins
using Escherichia coli. Protein Sci 2009, 18:936–948.
30. Houghten RA: General method for the rapid solid-phase synthesis of
large numbers of peptides: specificity of antigen-antibody interaction at
the level of individual amino acids. Proc Natl Acad Sci U S A 1985,
82:5131–5135.
31. Bozdech Z, Mok S, Hu G, Imwong M, Jaidee A, Russell B, Ginsburg H, Nosten
F, Day NP, White NJ, Carlton JM, Preiser PR: The transcriptome of
Plasmodium vivax reveals divergence and diversity of transcriptional
regulation in malaria parasites. Proc Natl Acad Sci U S A 2008,
105:16290–16295.
32. Rodriguez LE, Curtidor H, Urquiza M, Cifuentes G, Reyes C, Patarroyo ME:
Intimate molecular interactions of P. falciparum merozoite proteins
involved in invasion of red blood cells and their implications for vaccine
design. Chem Rev 2008, 108:3656–3705.
33. Yang C, Collins WE, Xiao L, Saekhou AM, Reed RC, Nelson CO, Hunter RL,
Jue DL, Fang S, Wohlhueter RM, Udhayakumar V, Lal AA: Induction of
protective antibodies in Saimiri monkeys by immunization with a
multiple antigen construct (MAC) containing the Plasmodium vivax
circumsporozoite protein repeat region and a universal T helper epitope
of tetanus toxin. Vaccine 1997, 15:377–386.
Moreno-Pérez et al. Malaria Journal 2013, 12:165 Page 9 of 9
http://www.malariajournal.com/content/12/1/16534. Oliveira-Ferreira J, Vargas-Serrato E, Barnwell JW, Moreno A, Galinski MR:
Immunogenicity of Plasmodium vivax merozoite surface protein-9
recombinant proteins expressed in E. coli. Vaccine 2004, 22:2023–2030.
35. Mongui A, Angel DI, Gallego G, Reyes C, Martinez P, Guhl F, Patarroyo MA:
Characterization and antigenicity of the promising vaccine candidate
Plasmodium vivax 34 kDa rhoptry antigen (Pv34). Vaccine 2009, 28:415–421.
36. Arevalo-Pinzon G, Curtidor H, Patino LC, Patarroyo MA: PvRON2, a new
Plasmodium vivax rhoptry neck antigen. Malar J 2011, 10:60.
37. Herrera S, De Plata C, Gonzalez M, Perlaza BL, Bettens F, Corradin G, Arevalo-
Herrera M: Antigenicity and immunogenicity of multiple antigen
peptides (MAP) containing P. vivax CS epitopes in Aotus monkeys.
Parasite Immunol 1997, 19:161–170.
38. Herrera S, Bonelo A, Perlaza BL, Fernandez OL, Victoria L, Lenis AM, Soto L,
Hurtado H, Acuna LM, Velez JD, Palacios R, Chen-Mok M, Corradin G,
Arevalo-Herrera M: Safety and elicitation of humoral and cellular
responses in colombian malaria-naive volunteers by a Plasmodium vivax
circumsporozoite protein-derived synthetic vaccine. Am J Trop Med Hyg
2005, 73:3–9.
39. Hisaeda H, Yasutomo K, Himeno K: Malaria: immune evasion by parasites.
Int J Biochem Cell Biol 2005, 37:700–706.
doi:10.1186/1475-2875-12-165
Cite this article as: Moreno-Pérez et al.: Characterizing PvARP, a novel
Plasmodium vivax antigen. Malaria Journal 2013 12:165.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
